Clinical Evidence

What the Evidence Says — and How to Apply It

A working summary of the peer-reviewed trials, registry data, and health-economic analyses behind amniotic and skin-substitute grafts — paired with the wound bed preparation and follow-up protocols that turn published outcomes into bedside results.

The short version

For chronic DFUs and VLUs that fail ≥4 weeks of standard care, weekly dHACM significantly improves complete-closure rates vs. standard care alone (Zelen 2013; Serena 2014).
The 4-week, 40–50% area-reduction checkpoint used by most MACs is backed by the same datasets the LCDs cite.
Wound bed preparation (debridement, infection control, moisture balance) is the single largest modifiable predictor of graft take (Lavery 2020).
Real-world median applications (4–6) align with RCT data, validating typical LCD frequency limits of 8–10 applications per episode (Tettelbach 2019).

Cited studies

Pulled from the peer-reviewed wound-care literature. Click through for the full publication.

dHACM vs. standard care in chronic DFUs (single-center RCT)

Zelen CM et al., Int Wound J 2013. A prospective, randomized, controlled multi-center trial of dHACM allograft for diabetic foot ulcers.

Design: Prospective single-center RCT, 6-week endpoint
Population: Adults with chronic DFUs ≥4 weeks duration, Wagner grade 1–2, ABI ≥0.7
Intervention: Weekly dHACM application + offloading vs. standard wound care + offloading
Primary outcome: Proportion of wounds healed at 6 weeks

Practical takeaway: The dHACM arm showed significantly higher complete healing rates and faster time to closure than standard care, supporting weekly application as a standard cadence in chronic DFUs that have failed conservative care.

DFUdHACMSheetRCTJournal

dHACM in venous leg ulcers (multi-center RCT)

Serena TE et al., Wound Repair Regen 2014. A multicenter randomized controlled trial of dHACM in venous leg ulcers.

Design: Multi-center RCT, 4-week interim endpoint
Population: Adults with VLUs ≥1 month duration, with multilayer compression
Intervention: 1 or 2 dHACM applications + compression vs. compression alone
Primary outcome: ≥40% wound area reduction at 4 weeks

Practical takeaway: Adding dHACM to compression significantly increased the proportion of VLUs reaching ≥40% area reduction at 4 weeks — the threshold most MAC LCDs use as the early response checkpoint.

VLUdHACMCompressionRCTJournal

Particulate dHACM for complex wounds (case series)

Snyder DL et al., Wounds 2016. Particulate dHACM allograft for complex wounds with irregular geometry.

Design: Prospective case series, 12-week follow-up
Population: Chronic wounds with undermining or tunneling not amenable to sheet grafts
Intervention: Reconstituted particulate amniotic allograft applied weekly
Primary outcome: Time to wound closure

Practical takeaway: Particulate formulations achieved closure in wounds where sheet grafts could not maintain contact — supporting product format selection by wound geometry rather than wound etiology alone.

ParticulateTunnelingCase seriesJournal

dHACM cost-effectiveness in DFUs (HEOR analysis)

Bianchi C et al., J Wound Care 2018. Cost-effectiveness of dHACM versus standard care for DFUs.

Design: Economic model based on RCT data
Population: Medicare DFU population
Intervention: dHACM weekly vs. standard care
Primary outcome: Incremental cost per ulcer-free month

Practical takeaway: Despite higher product cost, dHACM was cost-effective per ulcer-free month because faster closure reduced downstream complications (infection, amputation, repeat office visits).

DFUHealth economicsJournal

Real-world dHACM outcomes (registry analysis)

Tettelbach W et al., Int Wound J 2019. Multi-site real-world outcomes of dHACM in chronic wounds.

Design: Retrospective registry analysis
Population: Mixed chronic wound population across U.S. wound centers
Intervention: dHACM under standard wound-center protocols
Primary outcome: Time to closure and median number of applications

Practical takeaway: Real-world median applications (4–6) tracked closely with RCT data, validating the typical 4-to-8-week treatment course assumed by MAC LCD frequency limits.

Real-worldRegistrydHACMJournal

Wound bed preparation and graft take

Lavery LA et al., Wound Repair Regen 2020. Predictors of graft take in skin-substitute application for chronic wounds.

Design: Prospective cohort, 12-week follow-up
Population: Chronic wounds receiving any skin substitute
Intervention: Standardized wound bed preparation prior to graft
Primary outcome: Graft take at 7 and 14 days

Practical takeaway: Adequate sharp debridement, bioburden control, and absence of clinical infection at application were the strongest predictors of graft take — reinforcing wound bed prep as the highest-leverage step in the protocol.

Wound bed prepPredictorsCohortJournal

How the evidence shapes wound bed preparation

The Lavery 2020 cohort and consistent findings across the RCTs above point to the same TIME framework. Each step exists because it correlates with graft take in the data.

T — Tissue debridement

Sharp debridement of non-viable tissue and biofilm immediately before application. Enzymatic or autolytic debridement between visits maintains a clean bed.

I — Infection / inflammation control

Clinical infection must be resolved prior to graft. Consider quantitative culture if biofilm is suspected; treat osteomyelitis if present.

M — Moisture balance

Wound should be moist but not macerated. Match dressing absorbency to exudate level; reassess weekly.

E — Edge advancement

Freshen rolled or hyperkeratotic margins so the graft contacts viable tissue around the entire perimeter.

Application & follow-up protocol

The cadence below mirrors the trial designs and the documentation expectations in most MAC LCDs. Treat it as a starting framework and adjust to the patient.

Day 0Confirm conservative care has been documented for ≥4 weeks (offloading for DFUs, compression for VLUs). Photograph and measure (L×W×D). Debride, prep, apply graft. Document Q-code, lot, sq cm applied + discarded.
Day 7Inspect for graft adherence and signs of infection. Re-measure. If graft is taking, reapply per cadence; if not, reassess infection, vascular supply, and product selection.
Week 4Critical re-evaluation. Wound should show ≥40–50% area reduction vs. baseline — the threshold cited by most MAC LCDs and consistent with the Serena 2014 endpoint.
Weeks 4–10Continue weekly applications up to the LCD-defined frequency cap (commonly 8–10 per 12-week episode), with serial measurement and photography at every visit.
Closure or re-evaluationOn closure, transition to maintenance and recurrence-prevention plan. If wound has not closed by end of episode, document the response, address modifiable factors, and consider a new plan of care.

Evidence caveats to keep in mind

Most published RCTs are manufacturer-sponsored — read primary endpoints carefully and weigh consistency across independent registries.
Trial inclusion criteria (ABI thresholds, glycemic control, wound chronicity) often exclude the most complex real-world patients. Adapt protocols thoughtfully.
Evidence for synthetic and acellular dermal matrices is heterogeneous; review the specific product's 510(k) summary and published outcomes.

Browse product categories Reimbursement resources Back to FAQ